# Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Source: https://onco.cc/trials/nct04379596/  
OnCo record `nct04379596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) is a phase 2 interventional study registered as NCT04379596 by AstraZeneca, with 452 participants enrolled, started 2020-06-03 and due to reach its primary completion in 2027-05-04. Interventions recorded: Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab and Trastuzumab deruxtecan.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04379596
- Phase: 2
- Setting: A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
- Sponsor: AstraZeneca
- Enrolled: 452

## Sources

- ClinicalTrials.gov NCT04379596: https://clinicaltrials.gov/study/NCT04379596

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct04379596.json